BlueWind Medical Raises $47.8M for Incontinence Therapy

BlueWind Medical has successfully closed a significant funding round, bringing in $47.8 million through a mix of equity and debt. This capital infusion is earmarked to accelerate the commercial rollout of its innovative Revi System, a novel implantable tibial neuromodulation (ITNM) therapy designed to address urgency urinary incontinence (UUI).

The substantial financing will empower BlueWind Medical to bolster its commercial sales infrastructure and intensify market access strategies. These initiatives are crucial for broadening patient and healthcare provider adoption of the Revi System, a device that offers a new therapeutic avenue for a condition affecting millions globally. The urgency urinary incontinence market is substantial, with estimates suggesting a significant percentage of the adult population experiences symptoms, highlighting the unmet need for effective, long-term solutions.

This financial milestone follows a period of robust clinical validation for the Revi System. Notably, the company highlighted three-year outcomes from its pivotal OASIS study. These results demonstrated enduring therapeutic effectiveness, a strong safety profile, and an impressive 95% patient satisfaction rate at the 36-month mark, underscoring the system's potential to become a new standard of care.

The Revi System represents a patient-centric approach to ITNM. It involves a minimally invasive outpatient procedure to implant a device near the ankle. This implant then interfaces with an external wearable component to deliver targeted stimulation to the posterior tibial nerve. A key design advantage is its daily activation by the patient at home, eliminating the need for internal batteries or leads, thereby simplifying management and reducing potential complications.

“This financing reflects deep conviction in our team, our technology, and the opportunity ahead to establish Revi as the new standard of care,” stated Kerry Nelson, Chief Executive Officer of BlueWind Medical. He emphasized the significant need for durable and effective treatments for urgency urinary incontinence that integrate smoothly into patients' daily lives.

Echoing this sentiment, Stephen Armstrong, Chief Financial Officer at BlueWind Medical, added, “The capital allows us to scale our commercial organization, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy.” He also expressed gratitude for the ongoing investor confidence as the company embarks on its next growth phase, solidifying its position as a leader in implantable tibial neuromodulation for UUI.

The successful closure of this round positions BlueWind Medical to make significant inroads in the UUI treatment space. With a validated technology and a clear commercialization strategy, the company is well-equipped to capture market share in a sector ripe for innovation. The ITNM segment, while still developing, shows considerable promise as a less invasive alternative to existing treatments, potentially driving significant market expansion.